Loading...

PODCAST

Endocrine Deep Dives

Gurbir Gill, MD

The Endocrine Deep Dive covers advanced topics in endocrinology. Utilizing AI-driven synthetic audio discussions from my own study notes, each episode breaks down complex endocrine concepts. Comprehensive Legal & Medical Disclaimer: Endocrine Deep Dives and all associated content, materials, and digital assets are produced strictly for informational and educational purposes only. The program is intended solely for healthcare providers, medical fellows, residents, and students as a supplement to

education courses

All Episodes

00:22:56

Bone Turnover Markers

Endocrine Deep Dives ·

2026/10/06

PODCAST SUMMARY: Bone turnover markers provide dynamic, real-time biochemical assessment of skeletal metabolism by quantifying bone formation through serum osteocalcin and procollagen type 1 N-terminal propeptide alongside bone resorption via serum and urinary C-telopeptides. These analytes reflect rapid cellular activity months before dual-energy X-ray absorptiometry can detect significant mineral density changes, serving as essential clinical tools for monitoring antiresorptive and anabolic

en-us

00:23:11

Hyperparathyroidism: Surgery vs Bisphosphonates Timing

Endocrine Deep Dives ·

2026/10/05

Primary hyperparathyroidism management hinges on distinguishing symptomatic from asymptomatic disease and assessing surgical candidacy according to established biochemical and densitometric thresholds. Parathyroidectomy remains the only curative intervention, durably correcting hypercalcemia, halting bone mineral density loss, and reducing nephrolithiasis risk. Bisphosphonates offer a temporary medical alternative for severe hypercalcemia or when surgery is contraindicated, but they fail to address

en-us

00:27:28

Persistent Post Thyroidectomy Tingling Despite...

Endocrine Deep Dives ·

2026/10/02

Post thyroidectomy hypocalcemia typically presents with perioral tingling and neuromuscular irritability driven by transient or permanent hypoparathyroidism. Early clinical identification relies on eliciting Chvostek and Trousseau signs alongside monitoring ionized calcium levels. Management strategies incorporate oral calcium supplementation and active vitamin D analogues to maintain safe serum thresholds and prevent tetany, while severe symptomatic drops mandate prompt intravenous calcium

en-us

00:19:00

Real world use of Palopegteriparatide

Endocrine Deep Dives ·

2026/10/01

A long-acting parathyroid hormone prodrug engineered for continuous parathyroid hormone receptor type 1 activation via physiologic autocleavage. Once-daily administration maintains stable serum calcium and phosphate levels while lowering urinary calcium excretion. This physiologic replacement reduces hypercalciuria and nephrocalcinosis risks intrinsic to conventional therapy, enabling the elimination of therapeutic active vitamin D and large oral calcium supplements.

en-us

00:17:20

Everything About Palopegteriparatide

Endocrine Deep Dives ·

2026/09/30

Palopegteriparatide is a long-acting prodrug of parathyroid hormone designed for once-weekly subcutaneous administration in hypoparathyroidism. By providing sustained physiological systemic exposure, it normalizes serum calcium and urinary calcium excretion while eliminating the erratic fluctuations associated with conventional twice-daily short-acting teriparatide injections. Clinical trials demonstrate effective maintenance of normocalcemia independent of high-dose oral calcium and active vitamin

en-us

00:22:30

Levothyroxine Interactions and More and More

Endocrine Deep Dives ·

2026/09/29

Levothyroxine absorption is highly vulnerable to gastrointestinal disruptions and concurrent ingestions. Common culprits include calcium carbonate, ferrous sulfate, proton pump inhibitors, and fiber supplements, which bind the hormone or alter gastric pH. Co-administered agents or malabsorptive states necessitate strategic spacing of at least four hours or dosage recalibration based on free thyroxine and thyrotropin monitoring. Clinicians must systematically screen for dietary and pharmacological

en-us

00:26:16

Hunt for the Elusive Neuropeptides

Endocrine Deep Dives ·

2026/09/28

The intense rivalry between Roger Guillemin and Andrew Schally revolutionized neuroendocrinology through the isolation of hypothalamic releasing hormones. Following their initial collaboration at Baylor University, the two researchers pursued bitter, independent competition at the Salk Institute and the New Orleans Veterans Administration. Overcoming immense biochemical barriers, their laboratories utilized industrial scale processing of slaughterhouse tissue, extracting vanishingly small

en-us

00:25:41

IPSS Case Studies

Endocrine Deep Dives ·

2026/09/25

Inferior petrosal sinus sampling differentiates Cushing disease from ectopic adrenocorticotropic hormone secretion using simultaneous petrosal and peripheral venous hormone measurements. A normal pituitary magnetic resonance imaging does not exclude Cushing disease, necessitating sampling. Interpretation relies on central-to-peripheral adrenocorticotropic hormone gradients at baseline and following secretagogues like desmopressin or corticotropin-releasing hormone, utilizing a baseline gradient

en-us

00:22:54

Inferior petrosal sinus sampling

Endocrine Deep Dives ·

2026/09/24

Inferior petrosal sinus sampling is the diagnostic gold standard for localizing the source of adrenocorticotropic hormone dependent Cushing syndrome when pituitary imaging is non diagnostic or discordant. The procedure relies on comparing simultaneous central venous hormone concentrations from each petrosal sinus against peripheral levels, both at baseline and following administration of a secretagogue such as desmopressin or corticotropin releasing hormone. A central to peripheral gradient confirms

en-us

00:26:20

Testing for 1-25 dihydroxy Vitamin D

Endocrine Deep Dives ·

2026/09/23

Assessing nutritional vitamin D status requires measuring 25-hydroxyvitamin D, as serum 1,25-dihydroxyvitamin D is tightly regulated by parathyroid hormone, calcium, and phosphate, often remaining normal or paradoxically elevated in severe nutritional deficiency due to secondary hyperparathyroidism. Clinical ordering of 1,25-dihydroxyvitamin D must be strictly reserved for evaluating complex disorders of calcium homeostasis, granulomatous diseases, lymphomas, advanced chronic kidney disease, or rare

en-us

00:24:26

Insulin Analogs

Endocrine Deep Dives ·

2026/09/22

Modern insulin pharmacokinetics are determined by molecular engineering targeting hexamer dissociation and systemic absorption kinetics. Rapid-acting formulations incorporate amino acid substitutions and excipients to accelerate hexamer-to-monomer transition for postprandial glycemic coverage. In contrast, basal analogs utilize fatty-acid acylation to facilitate subcutaneous multi-hexamer depot formation or reversible albumin binding, extending half-lives and flattening therapeutic profiles

en-us

00:21:14

Insulin Icodec

Endocrine Deep Dives ·

2026/09/21

Insulin icodec, marketed as Awiqli, is a groundbreaking once-weekly basal insulin designed to simplify diabetes management by drastically reducing the number of required injections. Through its unique ability to bind to albumin, the medication maintains a long half-life of approximately eight days, providing steady glucose control for an entire week.

en-us

00:22:50

Thyroid Nodules and Dysphagia

Endocrine Deep Dives ·

2026/09/18

en-us

00:22:18

FHH vs Normo-hormonal PHPT

Endocrine Deep Dives ·

2026/09/17

Familial hypocalciuric hypercalcemia and normohormonal primary hyperparathyroidism present significant diagnostic overlap, both manifesting with hypercalcemia alongside inappropriately non-suppressed or normal intact parathyroid hormone levels. Differentiating these entities hinges on accurate assessment of renal calcium handling. Calculating the 24-hour urinary calcium-to-creatinine clearance ratio remains the standard initial screening tool, where a ratio below 0.01 strongly suggests familial

en-us

00:23:03

Everything about Cinacalcet

Endocrine Deep Dives ·

2026/09/16

Cinacalcet is a positive allosteric modulator of the parathyroid calcium-sensing receptor (CaSR) indicated for hypercalcemia in primary hyperparathyroidism (PHPT) when parathyroidectomy is unfeasible. By enhancing receptor sensitivity to ambient calcium, it suppresses parathyroid hormone (PTH) secretion, normalizing serum calcium in up to 76% of patients. Crucially, cinacalcet does not improve bone mineral density or alter urinary calcium excretion. Initiation starts at 30 mg twice daily with food,

en-us

00:22:14

Oncocytic Thyroid Carcinoma

Endocrine Deep Dives ·

2026/09/15

Oncocytic thyroid carcinoma, historically classified as a Hürthle cell variant of follicular carcinoma, represents a distinct clinical entity driven by mitochondrial DNA mutations and widespread chromosomal loss of heterozygosity. Pathologically defined by over 75 percent eosinophilic, mitochondria-dense cells, it exhibits an aggressive phenotype with heightened rates of distant metastasis and structural recurrence. Crucially, metabolic mitochondrial dysfunction leads to loss of sodium-iodide

en-us

00:22:22

Osteoporosis treatment in CKD

Endocrine Deep Dives ·

2026/09/14

PODCAST SUMMARY: Managing osteoporosis in chronic kidney disease requires navigating the overlap between osteopenia, osteoporosis, and CKD-metabolic bone disorder. DXA fails to differentiate osteoporosis from renal osteodystrophy sub-types like adynamic bone disease or osteomalacia, necessitating pre-treatment assessment of serum PTH, bone-specific alkaline phosphatase, and 25-hydroxyvitamin D, or bone biopsy when indicated. In advanced CKD (stages 4 to 5D), bisphosphonate clearance is compromised,

en-us

00:23:32

Glucocorticoid Induced Osteoporosis Management

Endocrine Deep Dives ·

2026/09/14

Glucocorticoid-induced osteoporosis represents the most prevalent form of secondary bone loss, driven by rapid osteoblast apoptosis, suppressed bone formation, and transiently elevated osteoclast-mediated resorption. Skeletal deterioration occurs rapidly within the first three months of therapy, independent of bone mineral density, necessitating early risk stratification with FRAX and Vertebral Fracture Assessment. Management mandates immediate daily calcium and vitamin D optimization alongside

en-us

00:24:27

Molecular Testing in Indeterminate Thyroid Nodules

Endocrine Deep Dives ·

2026/09/11

PODCAST SUMMARY: Fine-needle aspiration yields indeterminate cytopathology (Bethesda III/IV) in up to 30% of thyroid nodules, creating clinical management dilemmas between diagnostic hemithyroidectomy and conservative surveillance. Modern molecular testing panels utilize next-generation sequencing and gene expression classifiers to profile somatic mutations (BRAF, RAS), gene fusions (RET/PTC, PAX8-PPARG), and copy number alterations. High negative predictive value (rule-out) testing allows low-risk

en-us

00:20:09

Preventing Rebound Fractures After Denosumab.

Endocrine Deep Dives ·

2026/09/10

Denosumab withdrawal triggers a rapid rebound in bone remodeling, characterized by transient hyper-osteoclastogenesis, steep elevations in serum CTX/P1NP, and rapid loss of accumulated bone mineral density. This hyper-resorptive overshoot spikes the risk of multiple spontaneous rebound vertebral fractures within 3 to 12 months of a missed or delayed dose. Transitioning off denosumab requires a precise antiresorptive bridge, typically initiated with a potent bisphosphonate like intravenous zoledronic

en-us

116 results

Similar Podcasts

Edutainment Learning

Ralph Krauss

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Education Futures

Svenia Busson & Laurent Jolie

Out In The Hall

NHSA